Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Cytek Biosciences Inc (CTKB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: CTKB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $5.75
1 Year Target Price $5.75
| 1 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -58.32% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 449.64M USD | Price to earnings Ratio - | 1Y Target Price 5.75 |
Price to earnings Ratio - | 1Y Target Price 5.75 | ||
Volume (30-day avg) 6 | Beta 1.26 | 52 Weeks Range 2.37 - 7.63 | Updated Date 06/30/2025 |
52 Weeks Range 2.37 - 7.63 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-06-05 | When After Market | Estimate -0.04 | Actual -0.0272 |
Profitability
Profit Margin -5.71% | Operating Margin (TTM) -36.12% |
Management Effectiveness
Return on Assets (TTM) -3.51% | Return on Equity (TTM) -2.91% |
Valuation
Trailing PE - | Forward PE 370.37 | Enterprise Value 199925145 | Price to Sales(TTM) 2.28 |
Enterprise Value 199925145 | Price to Sales(TTM) 2.28 | ||
Enterprise Value to Revenue 1.01 | Enterprise Value to EBITDA -133.96 | Shares Outstanding 126659000 | Shares Floating 108229016 |
Shares Outstanding 126659000 | Shares Floating 108229016 | ||
Percent Insiders 9.16 | Percent Institutions 62.13 |
Analyst Ratings
Rating 3 | Target Price 5.75 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 3 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cytek Biosciences Inc
Company Overview
History and Background
Cytek Biosciences was founded in 2014. It focuses on developing and commercializing innovative cell analysis tools, advancing cytometry through Full Spectrum Profiling (FSP) technology.
Core Business Areas
- Cell Analysis Instruments: Develops and sells cell analysis instruments that utilize its Full Spectrum Profiling (FSP) technology. These instruments provide a more comprehensive view of cells compared to traditional flow cytometry.
- Reagents: Offers a range of reagents optimized for use with its cell analysis instruments, including fluorochrome-conjugated antibodies and other staining solutions.
- Services: Provides services such as instrument installation, training, and technical support to ensure customers can effectively use its products.
Leadership and Structure
The leadership team includes Wenbin Jiang, PhD (CEO), and other key executives. The organizational structure is designed to support research and development, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Aurora Cytometer: A full spectrum flow cytometer offering high resolution and sensitivity. Competitors include Thermo Fisher Scientific (TMO) and BD Biosciences (BDX). Market share data specific to Aurora is not publicly available, but Cytek is a growing player in the advanced flow cytometry market.
- Northern Lights Cytometer: A more compact and affordable full spectrum flow cytometer designed for a broader range of users. Competitors include Beckman Coulter (DHR) and Miltenyi Biotec. Again, specific market share data is unavailable but part of Cytek's overall cytometry market presence.
Market Dynamics
Industry Overview
The cell analysis market is driven by advancements in biomedical research, drug discovery, and clinical diagnostics. Increasing demand for high-throughput and multi-parameter analysis is fueling growth.
Positioning
Cytek Biosciences is positioned as an innovator in the flow cytometry market with its FSP technology, offering improved resolution and sensitivity compared to traditional methods. Their competitive advantage lies in their technology which enables more colours and more markers on one cell.
Total Addressable Market (TAM)
The TAM for flow cytometry is estimated to be several billion USD. Cytek is positioned to capture a significant share of this market by innovating and expanding their product offerings.
Upturn SWOT Analysis
Strengths
- Innovative Full Spectrum Profiling (FSP) technology
- High-resolution and high-sensitivity cell analysis
- Growing market share in advanced flow cytometry
- Strong customer support and training
- Proprietary reagent portfolio.
Weaknesses
- Smaller size compared to established players
- Limited brand recognition in some markets
- High reliance on innovation and product development
Opportunities
- Expanding into new geographic markets
- Developing new applications for FSP technology
- Acquiring complementary technologies or companies
- Partnerships with pharmaceutical and biotech companies
- Penetrating clinical diagnostics market.
Threats
- Competition from established players with greater resources
- Technological advancements by competitors
- Regulatory changes impacting the cell analysis market
- Economic downturn affecting research funding
Competitors and Market Share
Key Competitors
- TMO
- BDX
- DHR
Competitive Landscape
Cytek is well positioned against its competitors with their proprietary FSP technology. Their disadvantages include having less brand recognition.
Growth Trajectory and Initiatives
Historical Growth: Cytek has demonstrated strong revenue growth in recent years, driven by increased adoption of its FSP technology.
Future Projections: Analyst estimates suggest continued growth for Cytek, driven by increasing demand for advanced cell analysis solutions.
Recent Initiatives: Recent strategic initiatives include expanding its sales and marketing efforts, developing new products and applications, and building strategic partnerships.
Summary
Cytek Biosciences shows promise with its innovative FSP technology and growing market share. Its strengths lie in its technology. It should be wary of increased competition and changes in regulations, while strategically leveraging opportunities like market expansions and new applications.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Public filings (SEC)
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may vary. Consult with a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cytek Biosciences Inc
Exchange NASDAQ | Headquaters Fremont, CA, United States | ||
IPO Launch date 2021-07-23 | President, CEO & Chairman of the Board Dr. Wenbin Jiang Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 663 | Website https://cytekbio.com |
Full time employees 663 | Website https://cytekbio.com | ||
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. The company offers aurora and northern lights systems delivers cell analysis; aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; enhanced small particle detection; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. It serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. The company distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.